<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05002413</url>
  </required_header>
  <id_info>
    <org_study_id>2020-01622</org_study_id>
    <nct_id>NCT05002413</nct_id>
  </id_info>
  <brief_title>Nanomotion-based Resistell AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia and/or Sepsis</brief_title>
  <acronym>NANO-RAST</acronym>
  <official_title>NANO-RAST: Nanomotion-based Resistell AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia and/or Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Resistell AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innosuisse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HEMEX AG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Resistell AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blood culture samples from bacteremia patients positive for Gram-negative bacteria will be&#xD;
      tested for antibacterial susceptibility using Resistell AST device. The results will be&#xD;
      compared with current AST gold standard tests to calculate sensitivity, specificity, and&#xD;
      accuracy of Resistell AST device.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NANO-RAST: Nano-motion based Resistell AST to determine the antibiotic susceptibility of&#xD;
      bacteria causing bacteremia and sepsis Medical Device under Investigation is Resistell AST&#xD;
      Study Population Patients admitted at the study site with bacteremia considered to be due to&#xD;
      a pathogenic strain (E. coli, Klebsiella spp., Pseudomonas aeruginosa, and other&#xD;
      Enterobacteriaceae). Study Design: Prospective, observational, single arm study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2021</start_date>
  <completion_date type="Anticipated">June 6, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 6, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of Resistell AST</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>The primary endpoint will be the sensitivity of the device in detecting antibiotic susceptibility in blood samples positive for Gram-negative bacteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accuracy and Specificity of Resistell AST</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Accuracy and specificity of the device will be calculated to test the effectiveness of the device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Result (TTR)</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Time to Result (TTR) from the point the blood culture turns positive for Gram-negative bacteria to the point antibiotic susceptibility results are obtained from the Resistell AST device.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Bacteremia Sepsis</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Resistell AST</intervention_name>
    <description>The Resistell AST is intended for rapid antibiotic susceptibility testing of most common clinically relevant Gram-negative bacteria causing bloodstream infections (BSI) (bacteremia). In the scope of this study, the device will be used to test the susceptibility of Gram-negative bacteria, in particular Escherichia coli, Klebsiella spp., and other Enterobacteriaceae to antibiotics: ceftriaxone, meropenem and ciprofloxacin and Pseudomonas aeruginosa to ceftazidime, meropenem, ciprofloxacin and piperacillin-tazobactam (combination antibiotic).</description>
    <other_name>Resistell Antibiotic Susceptibility Test</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with bacteremia considered to be due to a pathogenic strain who have been&#xD;
        hospitalized at CHUV at the time of blood culture inoculation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: The patients meeting all the following criteria can be recruited in the&#xD;
        study:&#xD;
&#xD;
          -  patients over the age of 18 years who sign, or their relatives / legal representatives&#xD;
             sign the informed consent form;&#xD;
&#xD;
          -  patients with bacteremia considered to be due to a pathogenic strain;&#xD;
&#xD;
          -  patients hospitalized at CHUV at the time of blood culture inoculation;&#xD;
&#xD;
          -  samples that turn positive overnight or early morning and that are processed by the&#xD;
             clinical diagnostic laboratory in the morning before 12:00 (noon) from Monday to&#xD;
             Friday.&#xD;
&#xD;
        Exclusion Criteria The patients meeting any of the following criteria will be excluded from&#xD;
        the study:&#xD;
&#xD;
          -  patient is diagnosed with polymicrobial bacteremia;&#xD;
&#xD;
          -  samples can be excluded from the study during the processing of samples in case of&#xD;
             technical errors e.g. failure with attachment of cells, technical problem with the&#xD;
             device or sensor, operator's error, etc.&#xD;
&#xD;
        Note: in the event that the capacity of the Resistell instruments is reached for the day,&#xD;
        no more ICFs will be obtained for the day.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexander Sturm, Dr</last_name>
    <phone>0041795213719</phone>
    <email>alÃªx.sturm@resistell.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Danuta Cichocka, Dr</last_name>
    <phone>0041 798999188</phone>
    <email>danuta.cichocka@resistell.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de microbiologie CHUV R , Suisse +41 21 314 4056</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert Greub, Professor</last_name>
      <phone>0041 213144056</phone>
      <email>gilbert.greub@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Giorgia Caruana, Dr</last_name>
      <phone>0041 79 55 69785</phone>
      <email>Giorgia.Caruana@chuv.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bacteremia Sepsis Antibiotic Susceptibility Testing AST Gram-negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

